Association of metabolic syndrome and hyperuricemia with mortality in patients with chronic kidney disease: a UK biobank study Authors: Chengkai Wu, Chuqing Pan, Li Liu, Wenyuan Li Published: 2025 ABSTRACT AbstractBackgroundChronic kidney disease (CKD) has detrimental effects on health through multiple pathophysiological mechanisms, significantly reducing life expectancy and contributing to a substantial disease burden. Therefore, this study aims to explore the association of metabolic syndrome (MetS) and hyperuricemia (HUA) with all-cause and cardiovascular mortality in patients with chronic kidney disease (CKD).MethodsOverall, 28,278 patients with CKD, defined by estimated glomerular filtration rate < 60 mL/min/1.73 m2 or urine albumin creatinine ratio > 3 mg/mmol, MetS (≥ 3 of 5 criteria), and HUA (> 7.0 mg/dL in males, > 6.0 mg/dL in females) were assessed. The outcomes included all-cause and cardiovascular mortality. Associations were assessed using multivariate-adjusted Cox proportional hazards models and Kaplan–Meier survival analysis, supplemented by subgroup analyses and sensitivity tests.ResultsDuring a median follow-up of 13.21 years, 3564 all-cause deaths (17.28%) were recorded, including 1025 (4.97%) attributable to cardiovascular causes. After multiple adjustments, both HUA and MetS were strongly associated with all-cause and cardiovascular mortality. Patients with CKD and coexisting HUA or MetS exhibited a significantly higher risk of all-cause mortality (adjusted hazard ratio [aHR] = 1.45, 95% confidence interval [CI]: 1.30–1.62) and cardiovascular mortality (aHR = 2.09, 95% CI: 1.70–2.58) than those without HUA or MetS. Kaplan–Meier curves demonstrated that elevated uric acid levels and a high number of MetS components significantly reduced survival probability (P < 0.001), with an increasing trend as the uric acid levels and the number of MetS components increased. Subgroup and sensitivity analyses confirmed the robustness and consistency of our findings.ConclusionMetS and HUA significantly increased all-cause and cardiovascular mortality in patients with CKD, particularly in those with high uric acid levels and a high number of MetS components.Clinical trial numberNot applicable.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12882-025-04615-0.Keywords: Metabolic syndrome, Hyperuricemia, Chronic kidney disease, UK biobank Background Chronic kidney disease (CKD) has detrimental effects on health through multiple pathophysiological mechanisms, significantly reducing life expectancy and contributing to a substantial disease burden. According to the latest Global Burden of Disease Study, CKD affected approximately 19.9% of the global population in 2021 [1]. Considering that CKD is an irreversible and progressive condition with limited therapeutic options, it has a high mortality rate. CKD results in 1.2 million deaths and 28.0 million years of life lost annually. The global all-cause mortality rate due to CKD increased by 41.5% between 1990 and 2017 [2]. By 2040, projections indicate that this will become the fifth leading cause of death worldwide, representing one of the largest increments among the major causes of death [3]. Furthermore, CKD often coexists with other diseases, further elevating the risk of mortality. Given these challenges, accurately identifying risk factors associated with CKD is crucial for effective patient management and reducing mortality rates. Metabolic syndrome (MetS) is a constellation of metabolic disorders characterized by five key components: central obesity, hypertension, hyperglycaemia, hypertriglyceridaemia, and low levels of high-density lipoprotein cholesterol (HDL-C) [4]. Globally, the prevalence of MetS is substantial and continues to rise dramatically, with reported rates of 34.7% among adults (2011–2016) [5] and an increase from 25.8% to 33.9% in the Chinese population (2008–2010) [6]. Extensive evidence indicates that MetS increases the risk of CKD, which is elevated in patients with a high number of MetS components [7, 8]. Previous studies have suggested that each component contributes to alterations in renal microcirculation, promoting inflammation and oxidative stress, ultimately exacerbating kidney injury through synergistic effects [9]. Although the underlying mechanisms remain unclear, comorbid MetS leads to poor health outcomes in patients with CKD. Hyperuricemia (HUA), the second most prevalent metabolic disorder globally [10], consistently co-occurs with MetS. Substantial research indicates a significant interaction and causal relationship between high uric acid (UA) levels and MetS. HUA has been implicated in the modulation of inflammatory processes [11] and is strongly associated with multiple metabolic disorders, including all the components of MetS [12, 13]. In contrast, HUA is positively correlated with multiple established risk factors for MetS, such as body mass index (BMI) and triglyceride-glucose index [14, 15]. Moreover, studies have demonstrated that HUA, regardless of MetS status, is a key contributor to an increased risk of CKD onset and progression and premature mortality in patients with CKD [16]. This association may be mediated by mechanisms such as endothelial dysfunction, heightened oxidative stress, and renin-angiotensin system activation [16, 17]. The pathogenic pathways of HUA and MetS significantly overlapped with those that induce renal injury, suggesting that both conditions exacerbate kidney damage through similar mechanisms. These findings highlight the importance of exploring their combined effects on patients with CKD. Accumulating evidence has established MetS and HUA as independent risk factors for CKD development, yet their associations with mortality outcomes in patients with CKD have received limited attention. Therefore, we conducted a comprehensive analysis of UK Biobank (UKBB) data to evaluate the mortality impact of MetS and HUA in the CKD population. Methods Study design and participants The study population was selected from the UKBB database (2006–2010) [18]. The UKBB is one of the largest prospective population-based cohorts across the United Kingdom and has recruited more than 500,000 participants since recruitment began in 2006. Extensive data were collected from the baseline database, including demographic, physical, and biochemical measurements; medical history; genetics; lifestyle; and medical conditions (self-reported and doctor-diagnosed), providing a valuable resource for studying disease risk, progression, and prevention. All participants provided consent for their health to be monitored, and the assessments were conducted at 22 centres across Scotland, England, and Wales. Mortality data in the UKBB were obtained by linking the National Death Registry with its database, with detailed methods available at https://biobank.ndph.ox.ac.uk/ukb/field.cgi?id=40001. The UKBB received ethical approval from the NHS National Research Ethics Service (no:16/NW/0274) and this study was conducted under application number 532,248. We identified 28,278 participants with evidence of CKD at baseline from the UKBB. The CKD-EPI Creatinine Eq. (2021) [19] was used to calculate the estimated glomerular filtration rate (eGFR), without considering race. Participants without data on serum creatinine, urine albumin, or creatinine levels were excluded. According to the “Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Guidelines,” CKD was defined as an eGFR < 60 mL/min/1.73 m2 or a random urine albumin creatinine ratio (UACR) > 3 mg/mmol [20]. According to the KDIGO risk classification this study further stratified into three categories: “Moderately Increased Risk”, “High Risk”, and “Very High Risk”. After excluding participants with insufficient data on HUA and MetS, we excluded those with missing data on the covariates of interest. The final analysis included 20,625 participants. A flowchart of the participant selection process is provided in Fig. 1. Flowchart of participant selection in this study. eGFR, estimated glomerular filtration rate; UACR, urinary albumin-to-creatinine ratio; HUA, hyperuricemia; MetS, metabolic syndrome Assessment of HUA and MetS Baseline UA levels were centrally measured by the UKBB using uricase-peroxidase-antiperoxidase analysis conducted to determine the presence of HUA, which was defined as UA levels exceeding 7.0 mg/dL in males and 6.0 mg/dL in females [21]. Based on the Joint Scientific Statement from the International Diabetes Federation, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, and International Association for the Study of Obesity in 2009 [22], the participants were diagnosed with MetS if they met at least three of the following five criteria: (1) elevated waist circumference, a measure of central obesity, was defined as ≥ 102 cm in men and ≥ 88 cm in women, consistent with AHA/NHLBI recommended cut points for waist circumference since most participants were of European descent; (2) high blood pressure (BP), defined as an average systolic BP ≥ 130 mmHg or diastolic BP ≥ 85 mmHg, derived from two baseline measurements (manual or machine-automated), or documented history of antihypertensive medication use; (3) Elevated fasting glucose (FG), defined as FG ≥ 100 mg/dL, or treatment to lower elevated FG; Of note, UKBB collected random blood biochemical results in a non-fasting state, and we referred to Eastwood’s method [23], using HbA1c ≥ 48 mmol/mol (6.5%) and random blood glucose ≥ 200 mg/dL to indicate hyperglycaemia even in the non-fasting state; (4) hypertriglyceridaemia, defined as triglyceride level ≥ 150 mg/dL; and (5) low-level of HDL-C, defined as HDL-C < 1.0 mmol/L in males and < 1.3 mmol/L in females. Covariates Data on the following covariates assessed in this study were collected by the UKBB using touchscreen questionnaires during recruitment [18]: age, sex, BMI level, educational level, annual household income, Townsend deprivation index (TDI), educational level, smoking status, alcohol intake, physical activity, baseline cancer status, eGFR and uACR. BMI levels were classified as underweight (< 18.5 kg/m²), normal weight (18.5–24.9 kg/m²), overweight (25.0–29.9 kg/m²), and obese (≥ 30.0 kg/m²). Education level was categorized as higher (college/university degree), school (A/O levels or equivalent), vocational (NVQ/HND/HNC or equivalent), and other (professional qualifications). Annual household income before tax was classified into three categories: < EUR 31,000, EUR 31,000–100,000, and > EUR 100,000. The TDI (from census/postcode, two decimals) was quartile-categorized. Smoking status was classified as never, previous, or current. Alcohol intake was categorized as never (no consumption), occasional (1–3 times/month), moderate (1–4 times/week), or heavy (daily/near-daily). Physical activity was classified according to the number of days of moderate or vigorous activity performed per week. Regular physical activity was defined as at least 150 min/week of moderate activity and 75 min/week of vigorous activity [24]. The baseline cancer status was defined as the date of cancer diagnosis before cohort entry. Outcomes The outcomes of this study included all-cause and cardiovascular mortality data sourced from the UKBB database. All-cause mortality data were obtained using the “date of death” field, with death status assessed as of December 31, 2021. Cardiovascular mortality was determined according to the “primary cause of death” field, with cases identified by matching International Classification of Diseases, Tenth Revision, codes within the range of I00–I99. In this study, participants with no data on the time of death were assumed to be alive based on the cutoff date. Statistical analysis The baseline characteristics were described according to the presence or absence of all-cause and cardiovascular mortality. Continuous variables were summarised as mean (standard deviation [SD]) when normally distributed and as median (interquartile range [IQR]) otherwise. Categorical variables were reported as counts (percentage, %). Baseline characteristics were compared between the groups using t-tests or Kruskal–Wallis H-tests, depending on their distribution, while categorical variables were analyzed using a chi-square test. Follow-up duration in person-years was calculated from the date of arrival at the assessment centre until the occurrence of the following: death from any cause, loss to follow-up, or uniform censoring date (December 31, 2021). Potential confounders were selected according to prior evidence indicating associations with either the exposure or outcomes of interest. All candidate variables were subjected to univariate analyses to evaluate their potential relationships with outcomes. Cox proportional hazards regression models were used to evaluate the relationship between the disease state and risk of all-cause and cardiovascular mortality in patients with CKD. Disease status included HUA, MetS, their interaction groups (neither, no-no; HUA only, yes-no; MetS only, no-yes; both, yes-yes), and different combinations of MetS components. The results of the Cox regression are represented as adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs). Otherwise, the relative excess risk due to interaction (RERI) and attributable proportion (AP) were utilized to quantify the interaction effects. Furthermore, we analyzed the data of patients with CKD and coexisting HUA and MetS. To compare the survival probabilities, the participants were stratified by UA level quartiles and number of MetS components. Kaplan–Meier curves were used to visualize survival trends, and Cox proportional hazards regression models were used to assess the relationships between UA levels, MetS components, and mortality outcomes. To explore the potential modification, subgroup analyses were carried out, stratifying participants by sex, age group (< 60 and ≥ 60 years) and CKD risk group. Cox regression models were constructed in a stepwise manner to assess the associations. Model 1 was adjusted for age and sex, model 2 was further adjusted for BMI level, annual household income, education level, smoking status, alcohol intake, and physical activity, and model 3 was further adjusted for eGFR and uACR. It should be noted that model 3 reduces the total number of participants since missing eGFR or uACR data. All variables included in the adjustment models were selected according to their significance (P < 0.05) in the preliminary univariate analyses. To validate the robustness of our findings, we performed the following sensitivity analyses: (1) exclusion of patients categorized as “Very High Risk” at baseline to assess the impact of this high-risk profile, (2) exclusion of patients with baseline cancer to minimize confounding, (3) exclusion of participants with outcome events occurring within the first 2 years of follow-up to address potential reverse causality. All analyses were performed using R software (version 4.2.2), with a criterion of P < 0.05 considered statistically significant. Results Baseline characteristics of study participants After applying strict exclusion criteria, 20,625 patients with CKD were included in the final analysis. The baseline population comprised a balanced sex distribution (male-to-female ratio ≈ 1:1), with a mean age of 61.0 years (IQR: 54.0–66.0). HUA was present in 6270 participants (30.4%), with a median UA of 5.7 mg/dL (IQR: 4.6–6.9). In addition, the number of MetS components ranged from 0 to 5, with the presence of two components being the most frequent (n = 5440, 26.4%). MetS was identified in 9197 (44.6%) participants. At the end of the follow-up (December 31, 2021), 3564 deaths (17.28%) were recorded, including 1025 (4.97%) attributed to cardiovascular causes. The participants who died were more likely to be female, older, and to have high serum urate levels and more than three MetS components (P < 0.05) compared to the surviving participants (Table 1, Supplementary Table S1). Among the patients with CKD, 5520 had an eGFR > 60 mL/min/1.73 m², while 16,267 had a UACR < 30 mg/g. Based on the KDIGO guidelines, the patients were stratified into three CKD risk groups: 17,822 (86.4%) at moderately increased risk, 2040 (9.9%) at high risk, and 762 (3.7%) at very high risk (Table 2). At baseline, one participant was missing data on eGFR, and 2,592 were missing UACR measurements. Consequently, when performing multivariable-adjusted analysis according to model 3, the total analytical population consisted of 18,032 individuals. Unadjusted hazard ratios from univariable Cox regression for all baseline covariates are presented in Supplementary Table S2 as part of the preliminary variable screening. Table 1Baseline characteristics of CKD patients stratified by all-cause and cardiovascular mortalityOverallAll-cause mortalityCardiovascular mortalityNoYesP-valueNoYesP-value N 20,62517,061356419,6001025 Sex < 0.001< 0.001 Male10,305 (50.0)9125 (53.5)1180 (33.1)10,046 (51.3)259 (25.3) Female10,320 (50.0)7936 (46.5)2384 (66.9)9554 (48.7)766 (74.7)Age, years61.0(54.0, 66.0)60.0(53.0, 65.0)64.5(60.0, 67.0)< 0.00161.0(54.0, 65.0)65.0(60.0, 67.0)< 0.001eGFR†, mL/min/1.73 m294.7(75.0, 102.8)95.7(78.4, 103.5)86.3(58.2, 98.6)< 0.00195(76.1, 102.9)82.9(56.8, 98.1)< 0.001UACR†, mg/mmol51.1(35.1–99.3)50.1(35.1, 93.7)58.9(35.1, 138.3)< 0.00150.7(35.1, 97.1)64.5(36.5, 181.6)< 0.001UA, mg/dL5.7 (4.6, 6.9)5.6 (4.6, 6.8)6.2 (5.1, 7.6)< 0.0015.7 (4.6, 6.8)6.6 (5.4, 7.9)< 0.001 HUA < 0.001< 0.001 No14,355 (69.6)12,219 (71.6)2136 (59.9)13,808 (70.4)547 (53.4) Yes6270 (30.4)4842 (28.4)1428 (40.1)5792 (29.6)478 (46.6) Elevated waist circumference < 0.001< 0.001 No10,761 (52.2)9161 (53.7)1600 (44.9)10,354 (52.8)407 (39.7) Yes9864 (47.8)7900 (46.3)1964 (55.1)9246 (47.2)618 (60.3) Hypertriglyceridaemia < 0.001< 0.001 No10,377 (50.3)8745 (51.3)1632 (45.8)9926 (50.6)451 (44.0) Yes10,248 (49.7)8316 (48.7)1932 (54.2)9674 (49.4)574 (56.0) High BP < 0.001< 0.001No4218 (20.5)3586 (21.0)632 (17.7)4046 (20.6)172 (16.8)Yes16,407 (79.5)13,475 (79.0)2932 (82.3)15,554 (79.4)853 (83.2) Elevated FG < 0.001< 0.001No14,390 (69.8)12,313 (72.2)2077 (58.3)13,863 (70.7)527 (51.4)Yes6235 (30.2)4748 (27.8)1487 (41.7)5737 (29.3)498 (48.6) Low HDL-C < 0.001< 0.001No14,815 (71.8)12,487 (73.2)2328 (65.3)14,183 (72.4)632 (61.7)Yes5810 (28.2)4574 (26.8)1236 (34.7)5417 (27.6)393 (38.3) MetS component counts < 0.001< 0.001 01498 (7.3)1362 (8.0)136 (3.8)1476 (7.5)22 (2.1) 14490 (21.8)3898 (22.8)592 (16.6)4363 (22.3)127 (12.4) 25440 (26.4)4544 (26.6)896 (25.1)5188 (26.5)252 (24.6) 34809 (23.3)3913 (22.9)896 (25.1)4523 (23.1)286 (27.9) 43173 (15.4)2432 (14.3)741 (20.8)2930 (14.9)243 (23.7) 51215 (5.9)912 (5.3)303 (8.5)1120 (5.7)95 (9.3) MetS < 0.001< 0.001 No11,428 (55.4)9804 (57.5)1624 (45.6)11,027 (56.3)401 (39.1) Yes9197 (44.6)7257 (42.5)1940 (54.4)8573 (43.7)624 (60.9) Interaction of HUA and MetS status < 0.001< 0.001 No-no8861 (43.0)7736 (45.3)1125 (31.6)8606 (43.9)255 (24.9) Yes-no2567 (12.4)2068 (12.1)499 (14.0)2421 (12.4)146 (14.2) No-yes5494 (26.6)4483 (26.3)1011 (28.4)5202 (26.5)292 (28.5) Yes-yes3703 (18.0)2774 (16.3)929 (26.1)3371 (17.2)332 (32.4) Cancer < 0.0010.201 No17,928 (86.9)15 095 (88.5)2833 (79.5)17,051 (87.0)877 (85.6) Yes2697 (13.1)1966 (11.5)731 (20.5)2549 (13.0)148 (14.4)†Results after excluding missing data. BMI, body mass index; TDI, Townsend deprivation index; eGFR, estimated glomerular filtration rate; UACR, urine albumin-to-creatinine ratio; UA, uric acid; HUA, hyperuricemia; BP: blood pressure; FG: fasting glucose; HDL-C: high-density lipoprotein cholesterol; MetS, metabolic syndrome Baseline characteristics of CKD patients stratified by all-cause and cardiovascular mortality 61.0 (54.0, 66.0) 60.0 (53.0, 65.0) 64.5 (60.0, 67.0) 61.0 (54.0, 65.0) 65.0 (60.0, 67.0) 94.7 (75.0, 102.8) 95.7 (78.4, 103.5) 86.3 (58.2, 98.6) 95 (76.1, 102.9) 82.9 (56.8, 98.1) 51.1 (35.1–99.3) 50.1 (35.1, 93.7) 58.9 (35.1, 138.3) 50.7 (35.1, 97.1) 64.5 (36.5, 181.6) †Results after excluding missing data. BMI, body mass index; TDI, Townsend deprivation index; eGFR, estimated glomerular filtration rate; UACR, urine albumin-to-creatinine ratio; UA, uric acid; HUA, hyperuricemia; BP: blood pressure; FG: fasting glucose; HDL-C: high-density lipoprotein cholesterol; MetS, metabolic syndrome Table 2Baseline characteristics according to UACR, eGFR, and KDIGO CKD risk stratificationOverallAll-cause mortalityCardiovascular mortalityNoYesNoYes eGFR, mL/min/1.73 m 2 < 6015,122 (73.3)12,869 (75.4)2253 (63.2)14,495 (74.0)627 (61.2) ≥ 605502 (26.7)4191 (24.6)1311 (36.8)5104 (26.0)398 (38.8) Missing1 (0.0)1 (0.0)0 (0.0)1 (0.0)0 (0.0) UACR ≤ 301766 (8.6)1360 (8.0)406 (11.4)1652 (8.4)114 (11.1) > 3016,267 (78.9)13,574 (79.6)2693 (75.6)15,485 (79.0)782 (76.3) Missing2592 (12.6)2127 (12.5)465 (13.0)2463 (12.6)129 (12.6) KDIGO CKD risk Moderately increased17,822 (86.4)15,160 (88.9)2662 (74.7)17,116 (87.3)706 (68.9) High2040 (9.9)1481 (8.7)559 (15.7)1833 (9.4)207 (20.2) Very high762 (3.7)419 (2.5)343 (9.6)650 (3.3)112 (10.9)eGFR, estimated glomerular filtration rate; UACR, urine albumin-to-creatinine ratio; CKD, chronic kidney disease; KDIGO, Kidney Disease: Improving Global Outcome Baseline characteristics according to UACR, eGFR, and KDIGO CKD risk stratification eGFR, estimated glomerular filtration rate; UACR, urine albumin-to-creatinine ratio; CKD, chronic kidney disease; KDIGO, Kidney Disease: Improving Global Outcome Interaction effect between HUA and MetS on all-cause mortality During a median follow-up of 13.21 years (IQR: 12.37–14.04, total person-years: 258,997.71), all-cause mortality outcomes occurred in 1428 of 6270 with HUA (22.78%) and 1940 of 9197 with MetS (21.09%). Figure 2A shows the effect of disease status on all-cause mortality in patients with CKD. After adjustment for sex, age, and other covariates (model 3), HUA (aHR = 1.19, 95% CI: 1.10–1.29) and MetS (aHR = 1.25, 95% CI: 1.17–1.371.15–1.36) both showed an association with all-cause mortality. Patients with CKD with coexisting HUA and MetS exhibited a significantly higher risk of all-cause mortality than those without HUA or MetS (aHR = 1.45, 95% CI:1.30–1.62). However, measures of additive interaction—RERI = 0.11 (95% CI: − 0.07, 0.29) and AP = 0.08 (95% CI: − 0.04, 0.20)—were not statistically significant (Supplementary Table S3). Association of HUA and MetS with mortality in CKD: interaction effects. aHR, adjusted hazard ratio; CI, confidence interval; HUA, hyperuricemia; MetS, metabolic syndrome. Forest plots show the multivariable adjusted HRs of all-cause (A) and cardiovascular (B) mortality associated with different disease status in patients with CKD. HRs are adjusted for age, sex, BMI level, annual household income, education level, smoking status, alcohol intake, physical activity, eGFR and UACR Additionally, the Kaplan–Meier curves for patients with both HUA and MetS demonstrated that elevated UA levels and an increased number of MetS components strongly reduced the probability of survival (P < 0.001, Fig. 3A and B). The aHRs for different UA levels and MetS components in relation to all-cause mortality risk are shown in Fig. 4A and Supplementary Table S4. Compared to the lowest UA quartile (Q1), each higher quartile was associated with an outstanding elevated risk of all-cause mortality, with the highest quartile (Q4) showing a 1.82-fold (95% CI:1.39–2.38) increase in risk. Similarly, a high number of MetS components was associated with increased mortality risk, with a 1.24-fold (95% CI: 1,00–1.53) higher risk observed in those with five components than those with three components. Survival rates by UA levels and MetS components in CKD. UA, uric acid; MetS, metabolic syndrome; CKD, chronic kidney disease. Kaplan-Meier Curves show the survival probabilities of all-cause mortality by UA levels and MetS component counts in participants with CKD, HUA and MetS Association of UA levels and MetS components with mortality in CKD with HUA and MetS. aHR, adjusted hazard ratio; CI, confidence interval; UA, uric acid; MetS, metabolic syndrome; CKD, chronic kidney disease; HUA, hyperuricemia. Forest plots show the multivariable adjusted HRs of all-cause (A) and cardiovascular (B) mortality associated with UA levels and MetS component counts in patients with CKD, HUA and MetS. HRs are adjusted for age, sex, BMI level, annual household income, education level, smoking status, alcohol intake, physical activity, eGFR and UACR Interaction effect between HUA and MetS on cardiovascular mortality Among the patients with CKD, 478 cardiovascular deaths occurred in those with HUA (7.62%), and 624 occurred in those with MetS (6.78%). After adjusting for multiple variables (model 3), Fig. 2B show that HUA (aHR = 1.51, 95% CI: 1.31–1.75) and MetS (aHR = 1.46, 95% CI: 1.24–1.71) were significantly associated with cardiovascular mortality, while the presence of both HUA and MetS showed an even stronger association (aHR = 2.09, 95% CI: 1.70–2.58). The additive interaction measures, RERI = 0.28 (95% CI: − 0.13, 0.69) and AP = 0.13 (95% CI: − 0.06, 0.32), were not statistically significant. Results of all models in Supplementary Table S5. As shown in Fig. 3C and D, elevated UA levels were significantly associated with reduced survival due to cardiovascular death (P < 0.001), while changes in the number of MetS components did not show a significant trend (P = 0.1802). As shown in Fig. 4B, Cox proportional hazards analysis indicated that elevated UA levels, particularly in the high quartile (Q3: aHR = 1.60, 95% CI: 1.01–2.55; Q4: aHR = 2.03, 95% CI: 1.27–3.24), were significantly associated with increased cardiovascular mortality risk. Results of all models in Supplementary Table S6. Subgroup analysis The subgroup analyses were generally consistent with the primary findings, showing a higher risk of mortality in most subgroups when HUA and MetS coexisted. Higher all-cause and cardiovascular mortality rates were observed in females than in males. In the high-risk subgroup, the aHR for all-cause mortality was 1.49 (95% CI: 0.94–2.35), which was not statistically significant; however, a significant additive interaction was observed (RERI = 0.78, 95% CI: 0.22–1.35; AP = 0.53, 95% CI: 0.15–0.90). Furthermore, in the very high-risk subgroup, a significantly increased risk was observed with an aHR of 1.47 (95% CI: 1.00–2.16), along with evidence of a significant additive interaction (RERI = 0.61, 95% CI: 0.16–1.06; AP = 0.42, 95% CI: 0.09–0.74). Results for other subgroups are detailed in Table 3. Table 3Subgroup analysis of interaction status and mortality outcomes: all-cause and cardiovascular mortalitySubgroupInteraction of HUA and MetS statusAll-cause mortalityCardiovascular mortalityaHR (95% CI)P-valueaHR (95% CI)P-value Age < 60 (n = 8046)No-no1 (ref)1 (ref)Yes-no1.17 (0.90–1.51)0.2411.07 (0.64–1.78)0.800No-yes1.27 (1.03–1.57)0.0281.23 (0.81–1.86)0.330Yes-yes1.57 (1.24–1.98)< 0.0011.78 (1.15–2.75)0.010 RERI (95% CI) 0.13 [-0.26, 0.53]0.48 [-0.25, 1.21] AP (95% CI) 0.08 [-0.16, 0.33]0.27 [-0.12, 0.66] Age ≥ 60 (n = 9986)No-no1 (ref)1 (ref)Yes-no1.07 (0.93–1.23)0.3581.49 (1.14–1.95)0.003No-yes1.19 (1.06–1.34)0.0031.43 (1.13–1.79)0.002Yes-yes1.40 (1.23–1.60)< 0.0012.17 (1.71–2.76)< 0.001 RERI (95% CI) 0.14 [-0.06, 0.34]0.26 [-0.22, 0.74] AP (95% CI) 0.1 [-0.04, 0.24]0.12 [-0.1, 0.33] Sex: male (n = 9289)No-no1 (ref)1 (ref)Yes-no1.07 (0.92–1.24)0.3771.27 (0.97–1.66)0.085No-yes1.22 (1.08–1.38)0.0011.41 (1.12–1.77)0.003Yes-yes1.41 (1.23–1.61)< 0.0011.88 (1.48–2.40)< 0.001 RERI (95% CI) 0.11 [-0.1, 0.32]0.2 [-0.23, 0.64] AP (95% CI) 0.08 [-0.07, 0.23]0.11 [-0.12, 0.34] Sex: female (n = 8743)No-no1 (ref)1 (ref)Yes-no1.21 (0.96–1.52)01141.87 (1.15–3.06)0.012No-yes1.15 (0.96–1.39)0.1331.20 (0.78–1.85)0.411Yes-yes1.49 (1.22–1.82)< 0.0012.65 (1.74–4.04)< 0.001 RERI (95% CI) 0.13 [-0.21, 0.47]0.58 [-0.42, 1.58] AP (95% CI) 0.09 [-0.14, 0.31]0.22 [-0.14, 0.57]CKD group: Moderately increased (n = 15,552)No-no1 (ref)1 (ref)Yes-no1.13 (0.97–1.32)0.1081.70 (1.28–2.26)< 0.001No-yes1.21 (1.08–1.36)< 0.0011.46 (1.16–1.84)0.001Yes-yes1.36 (1.19–1.55)< 0.0012.05 (1.59–2.64)< 0.001 RERI (95% CI) 0.01 (-0.21, 0.24)-0.11 (-0.68, 0.46) AP (95% CI) 0.01 (-0.15, 0.17)-0.05 (-0.34, 0.23)CKD group: High (n = 1787)No-no1 (ref)1 (ref)Yes-no1.12 (0.82–1.53)0.4710.83 (0.49–1.40)0.482No-yes1.11 (0.83–1.50)0.4710.87 (0.54–1.42)0.583Yes-yes1.47 (1.10–1.96)0.0091.49 (0.94–2.35)0.092 RERI (95% CI) 0.23 (-0.19, 0.65)0.78 (0.22, 1.35) AP (95% CI) 0.16 (-0.13, 0.44)0.53 (0.15, 0.90)CKD group: Very high (n = 693)No-no1 (ref)1 (ref)Yes-no0.92 (0.63–1.34)0.6500.93 (0.44–1.98)0.851No-yes0.94 (0.60–1.48)0.8041.38 (0.61–3.11)0.437Yes-yes1.47 (1.00-2.16)0.0492.07 (0.99–4.30)0.052 RERI (95% CI) 0.61 (0.16, 1.06)0.76 (-0.25, 1.76) AP (95% CI) 0.42 (0.09, 0.74)0.37 (-0.14, 0.87)HUA, hyperuricemia; MetS, metabolic syndrome; aHR, adjusted hazard ratio; CI, confidence interval; RERI, relative excess risk due to interaction; AP, attributable proportion Subgroup analysis of interaction status and mortality outcomes: all-cause and cardiovascular mortality Age < 60 (n = 8046) Age ≥ 60 (n = 9986) Sex: male (n = 9289) Sex: female (n = 8743) CKD group: Moderately increased (n = 15,552) CKD group: High (n = 1787) CKD group: Very high (n = 693) HUA, hyperuricemia; MetS, metabolic syndrome; aHR, adjusted hazard ratio; CI, confidence interval; RERI, relative excess risk due to interaction; AP, attributable proportion Sensitivity analysis After excluding baseline very high-risk individuals, those with cancer, or those with outcome events within two years, the results remained consistent for the overall population, further confirming the robustness and reliability of the findings (Supplementary Tables S7–S9). Discussion In this large prospective cohort study, we observed that, compared to that in patients without HUA or MetS, the coexistence of HUA and MetS significantly increased the risk of all-cause and cardiovascular mortality in patients with CKD, although no significant additive interaction was observed. Additionally, further analysis revealed that among patients with CKD, HUA and MetS, the risk of all-cause and cardiovascular mortality was more pronounced in those with high UA levels and an increased number of MetS components. Subgroups and sensitivity analyses were performed to validate the robustness of the above results. This study provides further insight into the association among HUA, MetS, and CKD. MetS is associated with proteinuria and reduced renal function [25], and numerous studies have established it as an independent risk factor for CKD development. For instance, a German study on CKD reported that MetS was associated with an increased risk of all-cause mortality (HR = 1.26) and cardiovascular mortality (HR = 1.48) [26], consistent with the results of our study. To identify which specific features of MetS drive its association with mortality, we analyzed the differential mortality risk across all possible combinations of its five components using multivariate Cox proportional hazards model 3. Our analyses revealed that combinations involving elevated FG and low HDL-C (Supplementary Figure S1 and S2) were associated with significantly elevated risks of both all-cause and cardiovascular mortality. These two risk factors are typical clinical manifestations of insulin resistance (IR), which is also a common metabolic alteration associated with CKD progression. Therefore, the presence of comorbid MetS in patients with CKD may heighten the risk of all-cause and cardiovascular mortality, potentially mediated through IR-related pathways. A 3-year cohort study from China reported that IR was associated with CKD in patients with MetS but not in those without MetS [27]. Moreover, MetS was closely associated with cardiovascular disease. A case-control study revealed that MetS was associated with arterial stiffness even in the absence of hypertension [28], a finding that was further validated by the Northern Ireland Young Adult Heart Study [29]. Previous studies have established a strong association between elevated UA levels and CKD progression. A prospective study in a chronic renal insufficiency cohort revealed a nonlinear J-shaped relationship between baseline UA level and all-cause mortality, with a high range of markedly increasing risk [30]. Our findings are consistent with these observations, namely that the HUA group had a significantly higher risk of all-cause and cardiovascular mortality than the non-HUA group. These results suggest that elevated UA levels exacerbate the risks of CKD diagnosis and mortality. HUA directly impairs renal function through UA crystal formation and exacerbates CKD progression in complicated ways. Animal studies have provided valuable insights into the mechanisms underlying the upregulation of pro-inflammatory cytokines and the promotion of macrophage infiltration in the renal interstitium, thereby exacerbating renal inflammation and injury [31, 32]. However, UA-lowering therapies show inconsistent efficacy in slowing CKD progression, with benefits limited to low-risk patients [33]. Therefore, the effect of HUA on CKD may be modulated by other coexisting risk factors, such as MetS. Recent studies have identified associations between CKD and conditions such as HUA, hypertension, diabetes, and obesity [34–36]. However, previous research has focused on HUA, MetS, and new-onset CKD [37], few studies have examined their long-term impact on patients with CKD, particularly with regard to all-cause and cardiovascular mortality. To the best of our knowledge, this is the first study to demonstrate that the coexistence of MetS and HUA significantly increases all-cause and cardiovascular mortality in patients with CKD, with the association remaining statistically significant after multivariable adjustment including eGFR and UACR. Although no statistically significant additive interaction between HUA and MetS was observed in the overall study population, a significant interaction was identified in the very high-risk CKD subgroup. This indicates that the combined risk of exposure to multiple metabolic conditions is contingent upon the underlying disease severity, with synergistic effects on mortality becoming discernible only after the progression to advanced stages of CKD. Furthermore, when HUA, MetS, and CKD coexisted, the risk of all-cause mortality increased significantly with both elevated SUA levels and a greater number of MetS components. These findings align with the results of Pammer et al., who reported an increasing trend in HRs (HR: 1.5–2.5) with increasing MetS components [26]. Additionally, in terms of cardiovascular mortality, Kangas et al. showed that pulse wave velocity, a predictor of cardiovascular mortality [38], was higher in patients with both MetS and hypertension than in those with either condition alone [28]. Therefore, HUA and MetS may negatively affect CKD mortality through overlapping mechanisms, such as insulin resistance, inflammation, and other pathways. However, the causal pathways underlying the synergistic effects on mortality remain unclear and require further investigation. This study concurrently examines CKD, HUA, and MetS due to their shared underlying pathophysiological mechanisms. This integrated approach aligns with the American Heart Association’s (AHA) recently proposed Cardiovascular-Kidney-Metabolic (CKM) syndrome framework [39]. Our study population uniformly met the criteria for at least CKM Stage 2 according to AHA staging criteria. The findings provide empirical evidence supporting the CKM syndrome concept, demonstrating that—consistent with other CKM-related research—these conditions are independently and cumulatively associated with increased risks of both all-cause and CVD mortality [40, 41]. Our findings highlight the critical importance of integrated risk factor management in CKD, with particular emphasis on metabolic health. Clinical practice should implement routine metabolic screening together with individually tailored treatment targets. Integration of social determinants of health (SDOH) screening is also recommended to identify and address socioeconomic barriers. Furthermore, strengthening lifestyle interventions and self-management support is essential to improve long term patient outcomes. Even after multivariate adjustment, residual confounders such as medication, previous CVD and dietary habits may still influence the results. Additionally, the reliance on baseline data and lack of longitudinal follow-up limited our ability to track dynamic changes in key variables. Despite these limitations, the strengths of this study are noteworthy. Our research is based on a large UKBB cohort and, thus, benefits from rigorous quality control and a well-established follow-up system for data collection, significantly minimizing information and loss-to-follow-up biases. Thus, our finding that the coexistence of MetS and HUA increases the risk of all-cause and cardiovascular mortality in patients with CKD is robust. Nevertheless, further studies are needed to confirm the generalizability of these findings to other regions and populations. Conclusions Both MetS and HUA were significant risk factors for fatal outcomes in patients with CKD. Their coexistence exhibited a synergistic effect, increasing the risk of all-cause and cardiovascular mortality, particularly in patients with high UA levels and a high number of MetS components. These findings shed light on the intricate connections among HUA, MetS, and CKD while offering insights for designing novel strategies for managing patients with CKD. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements This study used data from the UK Biobank (Application number:532248). We express our deep gratitude to the participants of UKBB and acknowledge the essential efforts of the research and administrative teams involved in this work. Abbreviations Chronic kidney disease Metabolic syndrome High-density lipoprotein cholesterol Hyperuricemia Uric acid Body mass index UK Biobank Estimated glomerular filtration rate Kidney Disease: Improving Global Outcomes Urine albumin-to-creatinine ratio Blood pressure Fasting glucose Townsend Deprivation Index Standard deviation Interquartile range Hazard ratio Confidence interval Insulin resistance Author contributions CW: Resources, Data curation, Formal analysis, Writing - original draft, Writing - review & editing, Funding acquisition; CP: Conceptualization, Visualization, Writing - original draft, Writing - review & editing; LL: Supervision, Writing - review & editing; WL: Funding acquisition, Supervision, Writing - review & editing. All authors read and approved the final manuscript. Funding This work was supported by the National Key R&D Program of China (No. 2022YFC2505106 to Dr Li), the Key-Area Research and Development Program of Guangdong Province (No. 2019B020227004 to Dr Li), and the Medical Scientific Research Foundation of Guangdong Province of China (No. B2025689 to Mr Wu). Data availability The datasets analyzed in this study are not publicly available due to UKBB access restrictions. Researchers may apply for data access through the UKBB protocol. Declarations Ethics approval and consent to participate Ethical approval for UKBB data collection was granted by the NHS National Research Ethics Committee (no: 16/NW/0274). All research procedures were conducted in strict compliance with the Declaration of Helsinki principles, and written informed consent was obtained from every participant prior to their inclusion in the study. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Chengkai Wu and Chuqing Pan These authors are co-first authors with equal contributions. Contributor Information Li Liu, Email: liuli@i.smu.edu.cn. Wenyuan Li, Email: liwy666@i.smu.edu.cn. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets analyzed in this study are not publicly available due to UKBB access restrictions. Researchers may apply for data access through the UKBB protocol.